Low-dose pain patch for autism symptoms
Part of Mental health clinical trials.
This study tests whether a low-dose buprenorphine skin patch can help reduce symptoms of autism spectrum disorder in children and teenagers. It aims to see if the patch is safe and effective when used in addition to usual care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 6 and 18 years old.
- You must have a formal diagnosis of autism spectrum disorder (ASD).
- Your symptoms must be at least moderately severe, based on a doctor's rating.
- You must be able to attend all study visits with a parent or guardian who can supervise the treatment.
- You must not have other serious mental health conditions (except ADHD), recent seizures, or unstable heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether buspirone, a medication that helps with anxiety, can reduce anxiety in children and teens with autism. It is a 12-week study where participants receive buspirone or a placebo (a pill with no medicine) to see if it improves anxiety symptoms.
This trial tests if the drug pimavanserin can help reduce rigid or repetitive behaviors in people with autism spectrum disorder. It may be an option if you or your child struggle with these symptoms and want to try a new treatment.
This Phase 2 study tests whether diphenhydramine improves sleep in children with autism who have significant sleep problems. It requires sleep monitoring (watch data and sleep testing) and checking for side effects to see if the treatment is safe and helpful.
This Phase 2 study tests whether a single dose of N-acetylcysteine can improve “restricted and repetitive behaviors” in children with autism. It’s meant for kids who are stable and still in early puberty stages.
This trial tests if the steroid prednisone can help adults with moderate-to-severe autism who also have signs of immune system problems, like autoimmune disease or inflammation. It might offer a new treatment option for people whose autism is linked to immune activity.
This trial tests whether a specific supplement can help adults with Level 1 autism. It is open only to Italian-speaking participants aged 18–35 who do not have other major mental health or brain conditions.
Hear when a new Autism spectrum disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.